CY1113159T1 - Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις - Google Patents

Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις

Info

Publication number
CY1113159T1
CY1113159T1 CY20121100902T CY121100902T CY1113159T1 CY 1113159 T1 CY1113159 T1 CY 1113159T1 CY 20121100902 T CY20121100902 T CY 20121100902T CY 121100902 T CY121100902 T CY 121100902T CY 1113159 T1 CY1113159 T1 CY 1113159T1
Authority
CY
Cyprus
Prior art keywords
competitives
glucagon
preparation
compounds
health uses
Prior art date
Application number
CY20121100902T
Other languages
English (en)
Inventor
Scott Eugene Conner
Jianke Li
Guoxin Zhu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113159T1 publication Critical patent/CY1113159T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει καινοφανείς ενώσεις του Χημικού Τύπου I, ή φαρμακευτικώς αποδεκτά άλατα εξ αυτών, οι οποίες έχουν δραστηριότητα ανταγωνιστή ή αντίστροφου αγωνιστή του υποδοχέα γλυκαγόνης, ως επίσης και μεθόδους για την παρασκευή τέτοιων ενώσεων. Σε μια άλλη ενσωμάτωση η εφεύρεση αποκαλύπτει φαρμακευτικές συνθέσεις περιλαμβάνοντας ενώσεις του Χημικού Τύπου I ως επίσης και μεθόδους χρήσης αυτών για την αγωγή διαβητικών και άλλων σχετικών με το γλυκαγόνη μεταβολικών διαταραχών, και των παρόμοιων.
CY20121100902T 2005-11-17 2012-09-28 Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις CY1113159T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73762705P 2005-11-17 2005-11-17
EP06850109A EP1951661B1 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
CY1113159T1 true CY1113159T1 (el) 2016-04-13

Family

ID=38474434

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100902T CY1113159T1 (el) 2005-11-17 2012-09-28 Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις

Country Status (14)

Country Link
US (1) US7696248B2 (el)
EP (1) EP1951661B1 (el)
JP (1) JP5107253B2 (el)
CN (1) CN101309895B (el)
AU (1) AU2006340002B2 (el)
BR (1) BRPI0618349A2 (el)
CA (1) CA2629348C (el)
CY (1) CY1113159T1 (el)
DK (1) DK1951661T3 (el)
ES (1) ES2391109T3 (el)
PL (1) PL1951661T3 (el)
PT (1) PT1951661E (el)
SI (1) SI1951661T1 (el)
WO (1) WO2007106181A2 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551015A (en) * 2004-06-14 2010-07-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
KR20170085615A (ko) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102015641B (zh) * 2008-03-05 2014-01-01 武田药品工业株式会社 杂环化合物
EP3153501B1 (en) 2008-08-13 2018-11-28 Metabasis Therapeutics, Inc. Glucagon antagonists
US8361959B2 (en) 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
PE20100443A1 (es) * 2009-02-06 2010-06-25 Takeda Pharmaceutical Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8748624B2 (en) * 2011-05-23 2014-06-10 Janssen Pharmaceutica Nv Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
WO2012162409A1 (en) * 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Biphenyl derivatives useful as glucagon receptor antagonists
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2013147026A1 (ja) * 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2016052300A (ja) * 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
IL146006A0 (en) * 1999-05-17 2002-07-25 Novo Nordisk As Glucagon antagonists/inverse agonists
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
EP1519723A1 (en) 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2004056763A2 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Novel glucagon antagonists
AU2006227435A1 (en) 2005-03-21 2006-09-28 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives

Also Published As

Publication number Publication date
CN101309895A (zh) 2008-11-19
BRPI0618349A2 (pt) 2011-08-23
AU2006340002B2 (en) 2011-12-22
EP1951661B1 (en) 2012-08-08
WO2007106181A2 (en) 2007-09-20
PL1951661T3 (pl) 2012-12-31
US20080300308A1 (en) 2008-12-04
WO2007106181A3 (en) 2007-12-06
DK1951661T3 (da) 2012-09-03
CN101309895B (zh) 2012-10-03
JP2009519226A (ja) 2009-05-14
JP5107253B2 (ja) 2012-12-26
CA2629348C (en) 2013-08-13
ES2391109T3 (es) 2012-11-21
CA2629348A1 (en) 2007-09-20
US7696248B2 (en) 2010-04-13
AU2006340002A1 (en) 2007-09-20
SI1951661T1 (sl) 2012-11-30
EP1951661A2 (en) 2008-08-06
PT1951661E (pt) 2012-09-19

Similar Documents

Publication Publication Date Title
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
GT200500309A (es) Derivados de sulfonilbencilimidazol
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
CY1112284T1 (el) Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
CY1113374T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
CY1115436T1 (el) Αναστολεις της κινασης p70 s6